Kiniksa Pharmaceuticals Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Kiniksa Pharmaceuticals wird ein Gewinn- und Umsatzwachstum von 44.1% bzw. 18.7% pro Jahr prognostiziert, während der Gewinn pro Aktie um 43.2% pro Jahr wachsen soll.
Wichtige Informationen
44.1%
Wachstumsrate der Gewinne
43.2%
EPS-Wachstumsrate
| Biotechs Gewinnwachstum | 24.6% |
| Wachstumsrate der Einnahmen | 18.7% |
| Zukünftige Eigenkapitalrendite | n/a |
| Analystenabdeckung | Good |
| Zuletzt aktualisiert | 19 May 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Apr 25
Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates
Mar 01Recent updates
Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
Apr 25Kiniksa Pharmaceuticals: Arcalyst Performs While Abiprubart Plans Take Shape
Apr 24Kiniksa Pharmaceuticals, Ltd. Just Reported A Surprise Profit And Analysts Updated Their Estimates
Mar 01We're Not Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn
Feb 28The Market Doesn't Like What It Sees From Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Revenues Yet
Dec 18We're Interested To See How Kiniksa Pharmaceuticals (NASDAQ:KNSA) Uses Its Cash Hoard To Grow
Nov 10Investors Don't See Light At End Of Kiniksa Pharmaceuticals, Ltd.'s (NASDAQ:KNSA) Tunnel
Apr 18Investors Shouldn't Be Too Comfortable With Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Robust Earnings
Nov 10Industry Analysts Just Upgraded Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Revenue Forecasts By 27%
Aug 04Kiniksa Pharmaceuticals GAAP EPS of -$0.29 beats by $0.15, revenue of $26.97M misses by $1.58M, reaffirms FY revenue guidance
Aug 03Analysts Are Updating Their Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Estimates After Its First-Quarter Results
May 05We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Mar 18Kiniksa: Latest Earnings Beat Shows Light At The End Of The Tunnel
Nov 25Is Kiniksa Pharmaceuticals (NASDAQ:KNSA) A Risky Investment?
Nov 04Kiniksa: Unexciting, Slow Growth Stock
Aug 13We're Keeping An Eye On Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Rate
Jul 31Kiniksa outlines development path for mavrilimumab after FDA feedback
Jun 08Kiniksa: A Look At Mavrilimumab
May 03Here's Why We're Not Too Worried About Kiniksa Pharmaceuticals' (NASDAQ:KNSA) Cash Burn Situation
Apr 17What Kind Of Investors Own Most Of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)?
Jan 02
Kiniksa's antibody treatment shows clinical benefit in late-stage COVID-19 study
Dec 22Dosing underway in Kiniksa Pharma's lumpy skin disease study with vixarelimab
Dec 15Kiniksa Pharma's KPL-404 shows encouraging action in early-stage study
Nov 30Kiniksa's vixarelimab nabs accelerated review in U.S. for a skin disorder
Nov 16Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 655 | 48 | 86 | 65 | 4 |
| 12/31/2025 | 536 | 42 | 81 | 60 | 6 |
| 12/31/2024 | 389 | -8 | 23 | 12 | 6 |
| 3/31/2024 | 302 | 9 | 21 | 22 | N/A |
| 12/31/2023 | 270 | 14 | 13 | 13 | N/A |
| 9/30/2023 | 249 | -7 | -3 | -3 | N/A |
| 6/30/2023 | 281 | 231 | 42 | 42 | N/A |
| 3/31/2023 | 236 | 196 | 38 | 38 | N/A |
| 12/31/2022 | 220 | 183 | 6 | 6 | N/A |
| 9/30/2022 | 177 | 143 | -2 | -2 | N/A |
| 6/30/2022 | 90 | -112 | -92 | -92 | N/A |
| 3/31/2022 | 71 | -134 | -123 | -123 | N/A |
| 12/31/2021 | 39 | -158 | -147 | -126 | N/A |
| 9/30/2021 | 20 | -175 | -169 | -149 | N/A |
| 6/30/2021 | 8 | -189 | -175 | -154 | N/A |
| 3/31/2021 | N/A | -184 | -165 | -145 | N/A |
| 12/31/2020 | N/A | -161 | -137 | -137 | N/A |
| 9/30/2020 | N/A | -140 | -122 | -120 | N/A |
| 6/30/2020 | N/A | -123 | -117 | -114 | N/A |
| 3/31/2020 | N/A | -122 | -129 | -127 | N/A |
| 12/31/2019 | N/A | -162 | -162 | -158 | N/A |
| 9/30/2019 | N/A | -173 | -167 | -162 | N/A |
| 6/30/2019 | N/A | -170 | -159 | -153 | N/A |
| 3/31/2019 | N/A | -153 | -136 | -129 | N/A |
| 12/31/2018 | N/A | -103 | -86 | -81 | N/A |
| 9/30/2018 | N/A | -93 | -78 | -77 | N/A |
| 6/30/2018 | N/A | -85 | -68 | -67 | N/A |
| 3/31/2018 | N/A | -76 | -60 | -60 | N/A |
| 12/31/2017 | N/A | -65 | N/A | -50 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: KNSADas prognostizierte Gewinnwachstum (44.1% pro Jahr) liegt über der Sparquote (2.4%).
Ertrag vs. Markt: KNSADie Erträge des Unternehmens (44.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (14.4% pro Jahr).
Hohe Wachstumserträge: KNSAEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: KNSADie Einnahmen des Unternehmens (18.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.4% pro Jahr).
Hohe Wachstumseinnahmen: KNSADie Einnahmen des Unternehmens (18.7% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von KNSA in 3 Jahren voraussichtlich hoch sein wird